Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.0%

61 terminated/withdrawn out of 290 trials

Success Rate

73.6%

-12.9% vs industry average

Late-Stage Pipeline

22%

63 trials in Phase 3/4

Results Transparency

77%

131 of 170 completed trials have results

Key Signals

22 recruiting131 with results51 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 1

89(38.0%)

Phase 2

76(32.5%)

Phase 3

54(23.1%)

Phase 4

9(3.8%)

N/A

5(2.1%)

Early Phase 1

1(0.4%)

234Total

Phase 1(89)

Phase 2(76)

Phase 3(54)

Phase 4(9)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (290)

Showing 20 of 290 trials

NCT07024563Phase 3Recruiting

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Role: lead

NCT07732361Completed

A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).

Role: lead

NCT05368038Enrolling By Invitation

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Role: collaborator

NCT05746559Phase 3Terminated

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Role: lead

NCT04933682Phase 1Completed

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Role: lead

NCT06374264Not ApplicableEnrolling By Invitation

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

Role: collaborator

NCT07081646Phase 1Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Role: lead

NCT04504825Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Role: lead

NCT05346354Phase 2Active Not Recruiting

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Role: lead

NCT01192425Completed

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes

Role: lead

NCT00546260Phase 2Terminated

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

Role: lead

NCT06079281Phase 3Active Not Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Role: lead

NCT06291376Phase 3Active Not Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Role: lead

NCT07596784Phase 3Not Yet Recruiting

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Role: lead

NCT07557420Phase 3Not Yet Recruiting

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Role: lead

NCT04543591Phase 3Completed

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Role: lead

NCT07157787Phase 2Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Role: lead

NCT05966467Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Role: lead

NCT06830798Phase 3Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Role: lead

NCT05389449Phase 3Active Not Recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Role: lead